NASDAQ:JANX

Janux Therapeutics (JANX) Stock Forecast, Price & News

$9.60

+0.04 (+0.42%)

(As of 09/22/2023 ET)

Compare

Today's Range: $9.30
▼
$9.94
50-Day Range: $9.56
▼
$14.00
52-Week Range: $9.26
▼
$23.64

Volume: 88,833 shs
Average Volume: 114,365 shs
Market Capitalization: $442.56 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $28.33

Janux Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 195.1% Upside
$28.33 Price Target
Short Interest: Bearish
9.91% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$6.17 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.81) to ($2.19) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Medical Sector

783rd out of 968 stocks

Pharmaceutical Preparations Industry

361st out of 445 stocks

3.5

Analyst's Opinion

Consensus Rating
Janux Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $28.33, Janux Therapeutics has a forecasted upside of 195.1% from its current price of $9.60.
Amount of Analyst Coverage
Janux Therapeutics has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
9.91% of the float of Janux Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Janux Therapeutics has a short interest ratio ("days to cover") of 29.6, which indicates bearish sentiment.
Change versus previous month
Short interest in Janux Therapeutics has recently increased by 1.72%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Janux Therapeutics does not currently pay a dividend.
Dividend Growth
Janux Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for JANX.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Janux Therapeutics this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for JANX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
1 people have added Janux Therapeutics to their MarketBeat watchlist in the last 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Janux Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,167,800.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
35.40% of the stock of Janux Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
75.39% of the stock of Janux Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Janux Therapeutics are expected to decrease in the coming year, from ($1.81) to ($2.19) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Janux Therapeutics is -5.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Janux Therapeutics is -5.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Janux Therapeutics has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Janux Therapeutics (NASDAQ:JANX) Stock

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. The company is also developing a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 and Cluster of Differentiation 28 designed to improve the anti-tumor activity of T cells. In addition, its PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors; EGFR-TRACTr is designed to target EGFR in various cancer types with multiple approved monoclonal antibodies; and TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target for which there is an approved anti-TROP2 antibody-drug conjugate. The company was incorporated in 2017 and is headquartered in San Diego, California.

JANX Price History

30 days | 90 days | 365 days | Advanced Chart

JANX Stock News Headlines

September 21, 2023 | americanbankingnews.com

Syros Pharmaceuticals (NASDAQ:SYRS) versus Janux Therapeutics (NASDAQ:JANX) Head-To-Head Analysis

August 10, 2023 | finance.yahoo.com

Wall Street Analysts Think Janux Therapeutics, Inc. (JANX) Could Surge 120.82%: Read This Before Placing a Bet

September 22, 2023 | Chaikin Analytics (Ad)

This is the #1 Stock to Buy for the AI Tidal Wave

Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.

August 8, 2023 | finance.yahoo.com

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Misses Revenue Estimates

August 8, 2023 | finance.yahoo.com

Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

August 1, 2023 | fool.com

Janux Therapeutics (NASDAQ: JANX)

July 25, 2023 | seekingalpha.com

Janux: Merck Deal, Loads Of Cash, Solid Early Data

July 20, 2023 | finance.yahoo.com

Wall Street Analysts Believe Janux Therapeutics, Inc. (JANX) Could Rally 120.65%: Here's is How to Trade

September 22, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

July 20, 2023 | finance.yahoo.com

All You Need to Know About Janux Therapeutics, Inc. (JANX) Rating Upgrade to Buy

July 20, 2023 | finance.yahoo.com

Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Could Be 28% Below Their Intrinsic Value Estimate

July 18, 2023 | seekingalpha.com

Janux Therapeutics prices ~$60M offering of shares, warrants

July 17, 2023 | markets.businessinsider.com

Janux Therapeutics' Stock Is Currently Undervalued, Analyst Highlights Prostate Cancer Candidate Potential

July 17, 2023 | finance.yahoo.com

Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs

June 5, 2023 | finance.yahoo.com

Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development

June 5, 2023 | finance.yahoo.com

Shareholders have faith in loss-making Janux Therapeutics (NASDAQ:JANX) as stock climbs 20% in past week, taking one-year gain to 29%

May 12, 2023 | msn.com

Wedbush Reiterates Janux Therapeutics (JANX) Outperform Recommendation

May 11, 2023 | msn.com

HC Wainwright & Co. Reiterates Janux Therapeutics (JANX) Buy Recommendation

May 9, 2023 | finance.yahoo.com

Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Tops Revenue Estimates

May 9, 2023 | finance.yahoo.com

Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

May 9, 2023 | seekingalpha.com

Janux Therapeutics Has Positive Catalysts And Could Get Cheaper

April 24, 2023 | finance.yahoo.com

Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences

April 20, 2023 | finance.yahoo.com

Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors

April 6, 2023 | msn.com

Janux initiated Outperform at Wedbush citing potential of platform technology

March 10, 2023 | msn.com

Janux Therapeutics GAAP EPS of -$0.39 beats by $0.10, revenue of $2.85M beats by $2.04M

March 10, 2023 | finance.yahoo.com

Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

February 14, 2023 | finance.yahoo.com

Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference

See More Headlines

Receive JANX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JANX Company Calendar

Last Earnings: 8/08/2023
Today: 9/22/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:JANX
CUSIP: N/A
CIK: 1817713
Web: www.januxrx.com
Phone: 858-751-4493
Fax: N/A
Employees: 67
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $28.33
High Stock Price Forecast: $35.00
Low Stock Price Forecast: $24.00
Forecasted Upside/Downside: +196.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.63)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-63,060,000.00
Net Margins: -862.89%
Pretax Margin: -872.45%
Return on Equity: -21.22%
Return on Assets: -18.68%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.28
Quick Ratio: 17.28

Sales & Book Value

Annual Sales: $8.61 million
Price / Sales: 51.19
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.70 per share
Price / Book: 1.24

Miscellaneous

Outstanding Shares: 46,100,000
Free Float: 29,781,000
Market Cap: $440.72 million
Optionable: Not Optionable
Beta: 1.57

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. David Alan Campbell Ph.D. (Age 63)
Pres, CEO & Director
Comp: $852.5k

Mr. Byron Robinson J.D. (Age 58)
Ph.D., Chief Strategy Officer
Comp: $606.8k

Mr. Tighe M. Reardon C.F.A. (Age 47)
CPA, CPA, Acting Chief Financial Officer

Mr. Tommy Diraimondo Ph.D.
Exec. Director of R&D

Mr. Charles M. Winter (Age 54)
Chief Technical Officer

Mr. James Pennington
Gen. Counsel

Ms. Brenda Van Vreeswyk
Head of HR

Mr. Andy Hollman Meyer (Age 39)
Chief Bus. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

JANX Stock - Frequently Asked Questions

Should I buy or sell Janux Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Janux Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" JANX shares.
View JANX analyst ratings or view top-rated stocks.
What is Janux Therapeutics' stock price forecast for 2023?: 3 equities research analysts have issued 1-year price targets for Janux Therapeutics' stock. Their JANX share price forecasts range from $24.00 to $35.00. On average, they anticipate the company's stock price to reach $28.33 in the next twelve months. This suggests a possible upside of 196.4% from the stock's current price.
View analysts price targets for JANX or view top-rated stocks among Wall Street analysts.
How have JANX shares performed in 2023?: Janux Therapeutics' stock was trading at $13.17 at the beginning of 2023. Since then, JANX stock has decreased by 27.4% and is now trading at $9.56.
View the best growth stocks for 2023 here.
When is Janux Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our JANX earnings forecast.
How were Janux Therapeutics' earnings last quarter?: Janux Therapeutics, Inc. (NASDAQ:JANX) released its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.10. The business had revenue of $1.06 million for the quarter, compared to analysts' expectations of $1.25 million. Janux Therapeutics had a negative net margin of 862.89% and a negative trailing twelve-month return on equity of 21.22%.
What ETF holds Janux Therapeutics' stock ?: Range Cancer Therapeutics ETF holds 8,898 shares of JANX stock, representing 1.13% of its portfolio.

When did Janux Therapeutics IPO?: (JANX) raised $152 million in an initial public offering (IPO) on Friday, June 11th 2021. The company issued 9,500,000 shares at $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager.
What is Janux Therapeutics' stock symbol?: Janux Therapeutics trades on the NASDAQ under the ticker symbol "JANX."
Who are Janux Therapeutics' major shareholders?: Janux Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BVF Inc. IL (8.90%), BlackRock Inc. (2.59%), Geode Capital Management LLC (0.82%), State Street Corp (0.72%), Northern Trust Corp (0.41%) and JPMorgan Chase & Co. (0.33%). Insiders that own company stock include Corp Bregua, Orbimed Advisors Llc and Ra Capital Management, LP.
View institutional ownership trends.
How do I buy shares of Janux Therapeutics?: Shares of JANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Janux Therapeutics' stock price today?: One share of JANX stock can currently be purchased for approximately $9.56.
How much money does Janux Therapeutics make?: Janux Therapeutics (NASDAQ:JANX) has a market capitalization of $440.72 million and generates $8.61 million in revenue each year. The company earns $-63,060,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis.
How can I contact Janux Therapeutics?: The official website for the company is www.januxrx.com. The company can be reached via phone at 858-751-4493 or via email at investors@janux.com.

This page (NASDAQ:JANX) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Janux Therapeutics (JANX) Stock Forecast, Price & News

Janux Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Janux Therapeutics (NASDAQ:JANX) Stock

JANX Price History

JANX Stock News Headlines

JANX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

JANX Stock - Frequently Asked Questions

Overall MarketRank^™